Korro Bio, Inc. (KRRO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Current obligations | 12.63M USD | Liabilities, Current |
| Cash and equivalents | 24.91M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 90.13M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $12.63M | $24.91M | $90.13M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $14.79M | $61.70M | $52.27M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $11.94M | $21.82M | $53.33M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $14.64M | $24.16M | $68.32M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $17.17M | $33.61M | $62.75M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $12.88M | $64.14M | $50.81M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $14.96M | $55.64M | $70.45M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $13.61M | $63.21M | $73.79M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $12.32M | $91.15M | $66.28M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $11.05M | $138.80M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $19.48M | $166.15M | (m) | (m) | (m) | (m) |
| 2023-11-03 | (m) | (m) | $36.60M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $9.61M | $41.72M | $0.00 | (m) | (m) | (m) |
| 2023-06-30 | (m) | $8.33M | $39.71M | $6.77M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $22.04M | $40.85M | $25.80M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $21.03M | $51.95M | $31.14M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $20.00M | $43.85M | $55.50M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $16.76M | $42.37M | $68.64M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $12.17M | $49.83M | $67.53M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $11.43M | $79.64M | $51.07M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $10.48M | $112.03M | $36.04M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $9.03M | $135.02M | $33.87M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $18.92M | $169.23M | $25.68M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $26.63M | $220.34M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $32.92M | $224.23M | $0.00 | (m) | (m) | (m) |
| 2020-06-30 | (m) | $41.16M | $195.38M | $0.00 | (m) | (m) | (m) |
| 2020-03-31 | (m) | $43.73M | $203.09M | $3.02M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $52.78M | $200.16M | $17.20M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $72.20M | $142.27M | $23.05M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $3.77M | $42.19M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |